Determination of the Absolute Bioavailability of GSK2118436 Following a Single Oral Dose Co-Administered With an Intravenous Radiolabelled Microtracer of GSK2118436 in Subjects With BRAF Mutant Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2017
At a glance
- Drugs Dabrafenib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- 04 Apr 2012 Actual patient number (4) added as reported by ClinicalTrials.gov.
- 04 Apr 2012 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov.
- 04 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.